298 related articles for article (PubMed ID: 25229569)
21. Identification of molecular apocrine breast tumours by microarray analysis.
Farmer P; Bonnefoi H; Becette V; Tubiana-Hulin M; Fumoleau P; Larsimont D; Macgrogan G; Bergh J; Cameron D; Goldstein D; Duss S; Nicoulaz AL; Brisken C; Fiche M; Delorenzi M; Iggo R
Oncogene; 2005 Jul; 24(29):4660-71. PubMed ID: 15897907
[TBL] [Abstract][Full Text] [Related]
22. Hedgehog pathway does not play a role in hidradenitis suppurativa pathogenesis.
Mozeika E; Jemec GB; Nürnberg BM
Exp Dermatol; 2011 Oct; 20(10):841-2. PubMed ID: 21824197
[TBL] [Abstract][Full Text] [Related]
23. Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa.
Kamp S; Fiehn AM; Stenderup K; Rosada C; Pakkenberg B; Kemp K; Dam TN; Jemec GB
Br J Dermatol; 2011 May; 164(5):1017-22. PubMed ID: 21250966
[TBL] [Abstract][Full Text] [Related]
24. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer.
Allegra JC; Lippman ME; Thompson EB; Simon R; Barlock A; Green L; Huff KK; Do HM; Aitken SC
Cancer Res; 1979 May; 39(5):1447-54. PubMed ID: 427788
[TBL] [Abstract][Full Text] [Related]
25. Tumour necrosis factor-alpha and matrix metalloproteinase-2 are expressed strongly in hidradenitis suppurativa.
Mozeika E; Pilmane M; Nürnberg BM; Jemec GB
Acta Derm Venereol; 2013 May; 93(3):301-4. PubMed ID: 23096596
[TBL] [Abstract][Full Text] [Related]
26. Interferon-gamma (IFN-γ) is Elevated in Wound Exudate from Hidradenitis Suppurativa.
Banerjee A; McNish S; Shanmugam VK
Immunol Invest; 2017 Feb; 46(2):149-158. PubMed ID: 27819528
[TBL] [Abstract][Full Text] [Related]
27. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemically defined subtypes and outcome of apocrine breast cancer.
Dellapasqua S; Maisonneuve P; Viale G; Pruneri G; Mazzarol G; Ghisini R; Mazza M; Iorfida M; Rotmensz N; Veronesi P; Luini A; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2013 Apr; 13(2):95-102. PubMed ID: 23245877
[TBL] [Abstract][Full Text] [Related]
29. Inflammation induced changes in the expression levels of components of the microRNA maturation machinery Drosha, Dicer, Drosha co-factor DGRC8 and Exportin-5 in inflammatory lesions of hidradenitis suppurativa patients.
Hessam S; Sand M; Skrygan M; Gambichler T; Bechara FG
J Dermatol Sci; 2016 Jun; 82(3):166-74. PubMed ID: 26917346
[TBL] [Abstract][Full Text] [Related]
30. What causes hidradenitis suppurativa?
Kurzen H; Kurokawa I; Jemec GB; Emtestam L; Sellheyer K; Giamarellos-Bourboulis EJ; Nagy I; Bechara FG; Sartorius K; Lapins J; Krahl D; Altmeyer P; Revuz J; Zouboulis CC
Exp Dermatol; 2008 May; 17(5):455-6; discussion 457-72. PubMed ID: 18400064
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous apocrine mixed tumor with intravascular tumor deposits: a diagnostic pitfall.
Kazakov DV; Kacerovska D; Skalova A; Zelger B; Schaller J; Shelekhova K; Michal M
Am J Dermatopathol; 2011 Dec; 33(8):775-9. PubMed ID: 21785330
[TBL] [Abstract][Full Text] [Related]
32. Surgical treatment of hidradenitis suppurativa: a 10-year experience.
Kagan RJ; Yakuboff KP; Warner P; Warden GD
Surgery; 2005 Oct; 138(4):734-40; discussion 740-1. PubMed ID: 16269303
[TBL] [Abstract][Full Text] [Related]
33. Managing patients with hidradenitis suppurativa.
Ball SL; Tidman MJ
Practitioner; 2016 May; 260(1793):25-9, 3. PubMed ID: 27382916
[TBL] [Abstract][Full Text] [Related]
34. Apocrine Gland-Rich Skin Has a Non-Inflammatory IL-17-Related Immune Milieu, that Turns to Inflammatory IL-17-Mediated Disease in Hidradenitis Suppurativa.
Jenei A; Dajnoki Z; Medgyesi B; Gáspár K; Béke G; Kinyó Á; Méhes G; Hendrik Z; Dinya T; Törőcsik D; Zouboulis CC; Prens EP; Bíró T; Szegedi A; Kapitány A
J Invest Dermatol; 2019 Apr; 139(4):964-968. PubMed ID: 30391261
[No Abstract] [Full Text] [Related]
35. Marjolin ulcer in hidradenitis suppurativa: case reports.
Grewal NS; Wan DC; Roostaeian J; Rubayi SR
Ann Plast Surg; 2010 Mar; 64(3):315-7. PubMed ID: 20179481
[TBL] [Abstract][Full Text] [Related]
36. Chronic hidradenitis suppurativa in the inguinal, perineal and scrotal regions. A case report and review of the literature.
Pironi D; Caruso F; Panarese A; Vendettuoli M; Mascagni D; Moraldi L; Filippini A
Ann Ital Chir; 2010; 81(6):465-70. PubMed ID: 21456485
[TBL] [Abstract][Full Text] [Related]
37. Hidradenitis Suppurativa and the Association With Hematological Malignancies.
Sotoodian B; Abbas M; Brassard A
J Cutan Med Surg; 2017; 21(2):158-161. PubMed ID: 27573126
[TBL] [Abstract][Full Text] [Related]
38. Boils at Frictional Locations in a Patient with Hidradenitis Suppurativa.
Boer J; Mihajlovic D
Acta Dermatovenerol Croat; 2016 Dec; 24(4):303-304. PubMed ID: 28128084
[TBL] [Abstract][Full Text] [Related]
39. Inherent differences in keratinocyte function in hidradenitis suppurativa: Evidence for the role of IL-22 in disease pathogenesis.
Jones D; Banerjee A; Berger PZ; Gross A; McNish S; Amdur R; Shanmugam VK
Immunol Invest; 2018 Jan; 47(1):57-70. PubMed ID: 28972431
[TBL] [Abstract][Full Text] [Related]
40. Pathogenesis and pharmacotherapy of Hidradenitis suppurativa.
Nazary M; van der Zee HH; Prens EP; Folkerts G; Boer J
Eur J Pharmacol; 2011 Dec; 672(1-3):1-8. PubMed ID: 21930119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
